“We are confident in our long-term growth strategies and our unique positioning of offering the high-touch service of an independent combined with the value and convenience of a national brand,” said President and Chief Executive Officer Charles Tyson. “In light of the current macroeconomic environment, we believe it is prudent to slow our new store opening cadence and allocate capital toward share repurchases under our current authorized plan.”
Citius Pharmaceuticals Announces Publication In Frontiers Of Immunology Of Results From Solid Tumor Study Of LYMPHIR In Combination With Checkpoint Inhibitor
Preclinical study demonstrates that adding LYMPHIR to anti-PD-1 treatment augments anti-tumor activity and improves overall survival compared to monotherapy alone by transiently depleting Tregs in the tumor
